Glycaemic control does not appear to correlate with mortality from COVID-19

Eunice O Wiafe, Jagannath Gopalappa, Vijay Jayagopal


COVID-19, diabetes, deaths, HbA1c, glycaemic control

Full Text:



GOV.UK. Deaths within 28 days of positive test. (accessed 20 August 2020).

Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020;8(9):782–92.

Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 2020;8(10):823–33.

Baron E, Bakhai C, Parthar K, et al. Association of type 1 and type 2 diabetes with COVID-19 related mortality in England: a whole population study. Lancet Diabetes Endocrinol 2020;8(10):813–22.

Booth CM, Latukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801–9.

Garbati MA, Fagbo SF, Fang VJ, et al. A comparative study of clinical presentation and risk factors for adverse outcome in patients hospitalised with acute respiratory disease due to MERS coronavirus or other causes. PLoS One 2016;11:e0165978.

Schoen K, Horvat N, Guerreiro NFC, de Castro I, de Giassi KS. Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity. BMC Infect Dis 2019;19(1):964.

Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109(5):531–8.

Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020;43(6):867–9.



  • There are currently no refbacks.

The Journal of the Association of British Clinical Diabetologists